Business / Corporate Dec 16, 2022
Japanese banks agree to back Toshiba’s preferred bidder, sources say
The four major banks are finalizing the details and could issue commitment letters as soon as the end of this month, the sources said.
Business / Corporate Nov 17, 2022
Toshiba preferred bidder may tap Rohm and Suzuki for funds
Electronics company Rohm is considering putting in about ¥100 billion in equity and around ¥200 billion in debt as part of efforts to back a bid for the group.
Business Nov 4, 2022
Toshiba’s preferred bidder may miss finance deadline
Four banks that were considering whether to issue commitment letters for loans to the consortium led by Japan Industrial Partners have decided not to proceed before the cutoff date.
Business / Corporate Oct 17, 2022
Toshiba sale faces delay as banks wary on financing
Some global banks have turned cautious over backing large buyouts like Toshiba amid rising borrowing costs in the United States and elsewhere.
Business Jun 22, 2022
Private equity giants derided as vultures eye breakthrough in Japan
A successful deal for Toshiba, which may be private equity’s largest ever in the country, would signal the once-criticized investors have become more accepted in Japan.
Business / Corporate Mar 23, 2022
Toshiba’s $4 billion elevator unit attracts interest from Midea and Otis
Shareholders are set to vote on Toshiba’s plan to split into two companies and sell noncore assets including the elevator operations.
Business / Corporate Apr 7, 2021
Toshiba shares surge on possible buyout by CVC Capital
The bid comes as Toshiba faces scrutiny from activists following a series of scandals, including a record fine for faulty accounting and billions of dollars in writedowns.
Business / Corporate | FOCUS May 11, 2018
Whisky-inspired code names cloaked Takeda's $62 billion Shire gamble in secrecy — until cover was blown
Takeda Pharmaceutical Co.'s ambitions to expand in the lucrative U.S. health care market led the drugmaker to begin a painstaking examination of Shire PLC's assets more than two years prior to striking a $62 billion deal. In particular, Shire's neuroscience unit and its gastrointestinal products ...